Related Experiment Videos
Response of neonatal hypocalcaemia to 1 alpha-hydroxyvitamin D3
Insights
1 alpha-hydroxyvitamin D3 (1 alpha-OH-D3) effectively and safely corrected hypocalcemia in neonates. This treatment was faster than traditional calcium gluconate infusions, offering a superior therapeutic option for infant hypocalcemia.
Area of Science:
- Neonatal Medicine
- Pediatric Endocrinology
- Pharmacology
Background:
- Neonatal hypocalcemia is a common clinical problem.
- Conventional treatment involves calcium gluconate infusions, which can be time-consuming.
- Alternative therapies are needed to expedite calcium level correction.
Purpose of the Study:
- To evaluate the efficacy and safety of 1 alpha-hydroxyvitamin D3 (1 alpha-OH-D3) in treating hypocalcemia in neonates.
- To compare the speed of correction and treatment outcomes between 1 alpha-OH-D3 and calcium gluconate infusions.
Main Methods:
- A cohort of 24 hypocalcemic neonates received 1 alpha-OH-D3.
- Serum calcium levels were monitored before and after treatment.
- A control group of 24 neonates received calcium gluconate infusions.
- Treatment duration and side effects were recorded.
Main Results:
- 1 alpha-OH-D3 significantly increased serum calcium levels in all treated infants within 48 hours.
- The mean time to correct hypocalcemia was significantly shorter with 1 alpha-OH-D3 (2.04 days) compared to calcium gluconate (4.12 days).
- No adverse side effects were observed during 1 alpha-OH-D3 treatment.
Conclusions:
- 1 alpha-OH-D3 is an effective and safe treatment for neonatal hypocalcemia.
- 1 alpha-OH-D3 offers a faster correction of hypocalcemia compared to calcium gluconate infusions.
- The ease of administration and lack of side effects make 1 alpha-OH-D3 a favorable therapeutic option.
Abstract:
Administration of 1 alpha-OH-D3 to hypocalcaemic neonates (mean +/- SD, serum calcium 1.50 +/- 0.13 mmol/l) significantly increased serum calcium in all 24 infants within 48 hours after starting therapy (mean +/- SD 1.83 +/- 0.23 mmol/1). The time required to correct hypocalcaemia was significantly shorter (2.04 +/- 0.56 days) in infants treated with 1 alpha-OH-D3, than in 24 infants treated with calcium gluconate infusions (4.12 +/- 1.0 days). Treatment with 1 alpha-OH-D3 was effective, easy to maintain, and produced no side effects.